Harvard Bioscience Inc. (NASDAQ:HBIO) posted its earnings results on Thursday. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.10. Harvard Bioscience had a negative net margin of 18.04% and a positive return on equity of 3.40%.

Harvard Bioscience (NASDAQ:HBIO) traded down 2.13% during trading on Thursday, reaching $2.30. Harvard Bioscience has a 12-month low of $2.25 and a 12-month high of $3.90. The company’s 50-day moving average price is $2.64 and its 200 day moving average price is $2.93. The stock’s market capitalization is $78.92 million.

Earnings History for Harvard Bioscience (NASDAQ:HBIO)

Large investors have recently added to or reduced their stakes in the stock. First Light Asset Management LLC increased its stake in Harvard Bioscience by 27.4% in the second quarter. First Light Asset Management LLC now owns 2,740,203 shares of the company’s stock worth $7,837,000 after buying an additional 590,010 shares during the period. Heartland Advisors Inc. increased its stake in Harvard Bioscience by 7.1% in the second quarter. Heartland Advisors Inc. now owns 2,200,000 shares of the company’s stock worth $6,292,000 after buying an additional 145,778 shares during the period. Dimensional Fund Advisors LP increased its stake in Harvard Bioscience by 0.9% in the second quarter. Dimensional Fund Advisors LP now owns 1,609,704 shares of the company’s stock worth $4,604,000 after buying an additional 14,198 shares during the period. Royce & Associates LP increased its stake in Harvard Bioscience by 17.0% in the first quarter. Royce & Associates LP now owns 1,546,000 shares of the company’s stock worth $4,669,000 after buying an additional 225,000 shares during the period. Finally, Acadian Asset Management LLC increased its stake in Harvard Bioscience by 4.4% in the third quarter. Acadian Asset Management LLC now owns 761,735 shares of the company’s stock worth $2,072,000 after buying an additional 31,956 shares during the period. 66.31% of the stock is owned by institutional investors.

Separately, Zacks Investment Research upgraded shares of Harvard Bioscience from a “sell” rating to a “hold” rating in a research note on Tuesday, July 12th.

About Harvard Bioscience

Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of specialized products, apparatus and scientific instruments. The Company’s products are used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories across the world.

5 Day Chart for NASDAQ:HBIO

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.